Akebia (AKBA) Therapeutics announced multiple positive business updates. As of January, Vafseo tablets are available in the U.S. for adult patients with anemia due to chronic kidney disease on ...

$AKBA insiders have traded $AKBA stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.

Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and ...

Short interest in Akebia Therapeutics Inc (NASDAQ:AKBA) increased during the last reporting period, rising from 14.07M to 16.68M. This put 7.72% of the company's publicly available shares short.

Akebia (AKBA) Therapeutics announced multiple positive business updates. As of January, Vafseo tablets are available in the U.S. for adult patients with anemia due to chronic kidney disease on ...

View Our Latest Analysis on AKBA Akebia Therapeutics Price Performance AKBA opened at $1.93 on Thursday. Akebia Therapeutics has a one year low of $0.80 and a one year high of $2.48. The business ...